A detailed history of Fragasso Group Inc. transactions in Amgen Inc stock. As of the latest transaction made, Fragasso Group Inc. holds 26,650 shares of AMGN stock, worth $7.46 Million. This represents 0.69% of its overall portfolio holdings.

Number of Shares
26,650
Previous 27,663 3.66%
Holding current value
$7.46 Million
Previous $8.64 Million 0.66%
% of portfolio
0.69%
Previous 0.74%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

SELL
$309.38 - $337.38 $313,401 - $341,765
-1,013 Reduced 3.66%
26,650 $8.59 Million
Q2 2024

Jul 08, 2024

SELL
$262.75 - $319.31 $248,036 - $301,428
-944 Reduced 3.3%
27,663 $8.64 Million
Q1 2024

Apr 10, 2024

BUY
$268.87 - $324.56 $90,878 - $109,701
338 Added 1.2%
28,607 $8.13 Million
Q4 2023

Jan 08, 2024

SELL
$255.7 - $288.46 $665,331 - $750,572
-2,602 Reduced 8.43%
28,269 $8.14 Million
Q3 2023

Dec 06, 2023

SELL
$218.65 - $271.46 $179,293 - $222,597
-820 Reduced 2.59%
30,871 $8.3 Million
Q2 2023

Jul 10, 2023

SELL
$214.27 - $253.37 $1.23 Million - $1.45 Million
-5,739 Reduced 15.33%
31,691 $7.04 Million
Q1 2023

Apr 13, 2023

BUY
$225.79 - $275.2 $109,959 - $134,022
487 Added 1.32%
37,430 $9.05 Million
Q4 2022

Jan 24, 2023

SELL
$229.03 - $291.01 $104,895 - $133,282
-458 Reduced 1.22%
36,943 $0
Q4 2022

Jan 24, 2023

SELL
$229.03 - $291.01 $8.46 Million - $10.8 Million
-36,943 Closed
0 $0
Q3 2022

Oct 13, 2022

SELL
$224.46 - $253.15 $4,489 - $5,063
-20 Reduced 0.05%
37,401 $8.43 Million
Q2 2022

Aug 30, 2022

BUY
$230.71 - $256.74 $267,854 - $298,075
1,161 Added 3.2%
37,421 $9.1 Million
Q1 2022

Apr 06, 2022

BUY
$219.27 - $242.57 $392,931 - $434,685
1,792 Added 5.2%
36,260 $8.77 Million
Q4 2021

Jan 19, 2022

BUY
$198.88 - $227.6 $419,437 - $480,008
2,109 Added 6.52%
34,468 $7.75 Million
Q3 2021

Oct 08, 2021

BUY
$212.27 - $248.7 $587,987 - $688,899
2,770 Added 9.36%
32,359 $6.88 Million
Q2 2021

Jul 19, 2021

BUY
$233.58 - $259.14 $505,700 - $561,038
2,165 Added 7.89%
29,589 $7.21 Million
Q1 2021

May 27, 2021

BUY
$221.91 - $258.6 $396,775 - $462,376
1,788 Added 6.97%
27,424 $6.82 Million
Q4 2020

Feb 04, 2021

BUY
$216.38 - $257.67 $204,046 - $242,982
943 Added 3.82%
25,636 $5.89 Million
Q3 2020

Nov 05, 2020

BUY
$234.65 - $260.95 $89,870 - $99,943
383 Added 1.58%
24,693 $6.28 Million
Q2 2020

Aug 10, 2020

BUY
$197.81 - $242.74 $8,505 - $10,437
43 Added 0.18%
24,310 $5.85 Million
Q1 2020

May 14, 2020

BUY
$182.24 - $241.7 $62,326 - $82,661
342 Added 1.43%
24,267 $4.92 Million
Q4 2019

Feb 13, 2020

BUY
$189.21 - $243.2 $155,909 - $200,396
824 Added 3.57%
23,925 $5.77 Million
Q3 2019

Nov 13, 2019

BUY
$174.11 - $208.62 $64,594 - $77,398
371 Added 1.63%
23,101 $4.47 Million
Q2 2019

Aug 13, 2019

BUY
$166.7 - $195.41 $186,704 - $218,859
1,120 Added 5.18%
22,730 $4.19 Million
Q1 2019

May 08, 2019

BUY
$180.87 - $203.88 $604,829 - $681,774
3,344 Added 18.31%
21,610 $4.11 Million
Q4 2018

Feb 12, 2019

BUY
$178.4 - $208.25 $23,370 - $27,280
131 Added 0.72%
18,266 $3.56 Million
Q3 2018

Nov 13, 2018

BUY
$185.29 - $208.89 $350,012 - $394,593
1,889 Added 11.63%
18,135 $3.47 Million
Q2 2018

Aug 01, 2018

SELL
$166.05 - $186.51 $49,150 - $55,206
-296 Reduced 1.79%
16,246 $3 Million
Q1 2018

May 14, 2018

SELL
$169.43 - $198.0 $16,095 - $18,810
-95 Reduced 0.57%
16,542 $2.82 Million
Q4 2017

Feb 09, 2018

BUY
$168.79 - $188.59 $165,245 - $184,629
979 Added 6.25%
16,637 $2.89 Million
Q3 2017

Nov 13, 2017

SELL
$167.29 - $191.0 $84,481 - $96,455
-505 Reduced 3.12%
15,658 $2.92 Million
Q3 2017

Nov 07, 2017

BUY
$167.29 - $191.0 $2.7 Million - $3.09 Million
16,163
16,163 $2.96 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $150B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Fragasso Group Inc. Portfolio

Follow Fragasso Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fragasso Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Fragasso Group Inc. with notifications on news.